{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:53:04Z","timestamp":1793141584996,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jdsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jdermsci.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T11:46:46Z","timestamp":1609328806000},"page":"174-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma"],"prefix":"10.1016","volume":"101","author":[{"given":"Wah Wah","family":"Aung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xibei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoki","family":"Horii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kie","family":"Mizumaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdermsci.2020.12.007_bib0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","article-title":"Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities","volume":"2","author":"Varga","year":"2017","journal-title":"J. Scleroderma Relat. Disord."},{"issue":"4","key":"10.1016\/j.jdermsci.2020.12.007_bib0010","first-page":"755","article-title":"Hypothesis: pathogenesis of systemic sclerosis","volume":"30","author":"Takehara","year":"2003","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2020.12.007_bib0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin. Exp. Immunol."},{"issue":"272","key":"10.1016\/j.jdermsci.2020.12.007_bib0020","article-title":"Pathogenesis of systemic sclerosis","volume":"6","author":"Pattanaik","year":"2015","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jdermsci.2020.12.007_bib0025","first-page":"275","article-title":"Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis","volume":"33","author":"Matsushita","year":"2006","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.jdermsci.2020.12.007_bib0030","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-017-0177-y","article-title":"The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells","volume":"15","author":"Seif","year":"2017","journal-title":"Cell Commun. Signal"},{"issue":"4","key":"10.1016\/j.jdermsci.2020.12.007_bib0040","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2020.12.007_bib0045","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.jdermsci.2020.12.007_bib0050","doi-asserted-by":"crossref","DOI":"10.4161\/jkst.24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAK-STAT"},{"issue":"9","key":"10.1016\/j.jdermsci.2020.12.007_bib0055","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.jdermsci.2020.12.007_bib0060","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","article-title":"Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease","volume":"12","author":"Kontzias","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2019","journal-title":"J. Scleroderma Relat. Disord."},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0070","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.jdermsci.2020.12.007_bib0075","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/art.39007","article-title":"Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice","volume":"67","author":"Nishimura","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-019-1963-2","article-title":"Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice","volume":"21","author":"Sendo","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.jdermsci.2020.12.007_bib0085","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s10875-015-0203-z","article-title":"Janus kinase inhibitor tofacitinib shows potent efficacy in a mouse model of autoimmune lymphoproliferative syndrome (ALPS)","volume":"35","author":"Yokoyama","year":"2015","journal-title":"J. Clin. Immunol."},{"issue":"7","key":"10.1016\/j.jdermsci.2020.12.007_bib0090","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aas9944","article-title":"BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance","volume":"4","author":"Matsushita","year":"2018","journal-title":"Sci. Adv."},{"issue":"7","key":"10.1016\/j.jdermsci.2020.12.007_bib0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/intimm\/dxz020","article-title":"Regulatory T cells in inflammatory skin disease: from mice to humans","volume":"31","author":"Kalekar","year":"2019","journal-title":"Int. Immunol."},{"issue":"9","key":"10.1016\/j.jdermsci.2020.12.007_bib0100","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","article-title":"T cells in systemic sclerosis: a reappraisal","volume":"51","author":"O\u2019Reilly","year":"2012","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0105","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/ar4430","article-title":"Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction","volume":"16","author":"Yang","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"9","key":"10.1016\/j.jdermsci.2020.12.007_bib0110","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1080\/14737159.2017.1356722","article-title":"An update on biomarker discovery and use in systemic sclerosis","volume":"17","author":"Matsushita","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"7770","key":"10.1016\/j.jdermsci.2020.12.007_bib0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41586-019-1467-x","article-title":"Opposing T cell responses in experimental autoimmune encephalomyelitis","volume":"572","author":"Saligrama","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0120","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41467-020-15857-x","article-title":"CD8+ regulatory T cells are critical in prevention of autoimmune-mediated diabetes","volume":"11","author":"Shimokawa","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11926-012-0297-8","article-title":"The immune pathogenesis of scleroderma: context is everything","volume":"15","author":"Greenblatt","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"issue":"5","key":"10.1016\/j.jdermsci.2020.12.007_bib0130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1586\/17469872.2013.835924","article-title":"Scleroderma: recent lessons from murine models and implications for future therapeutics","volume":"8","author":"Matsushita","year":"2013","journal-title":"Expert Rev. Dermatol."},{"issue":"11","key":"10.1016\/j.jdermsci.2020.12.007_bib0135","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1002\/art.34643","article-title":"Potential roles of interleukin-17A in the development of skin fibrosis in mice","volume":"64","author":"Okamoto","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jdermsci.2020.12.007_bib0140","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.3389\/fimmu.2018.02356","article-title":"Regulatory t cells in systemic sclerosis","volume":"9","author":"Frantz","year":"2018","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.jdermsci.2020.12.007_bib0145","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201899013","article-title":"A temporally dynamic Foxp3 autoregulatory transcriptional circuit controls the effector Treg programme","volume":"37","author":"Bending","year":"2018","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2018.11.008","article-title":"Regulatory and effector B cells: friends or foes?","volume":"93","author":"Matsushita","year":"2019","journal-title":"J. Dermatol. Sci."},{"issue":"2","key":"10.1016\/j.jdermsci.2020.12.007_bib0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jdermsci.2020.12.007_bib0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2016.10.005","article-title":"Impact of tofacitinib treatment on human B-cells in vitro and in vivo","volume":"77","author":"Rizzi","year":"2017","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jdermsci.2020.12.007_bib0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0090-1229(91)90016-4","article-title":"CD5+ B cells in autoimmune disease and lymphoid malignancy","volume":"59","author":"Shirai","year":"1991","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"6","key":"10.1016\/j.jdermsci.2020.12.007_bib0170","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/BOR.0000000000000218","article-title":"Update on macrophages and innate immunity in scleroderma","volume":"27","author":"Chia","year":"2015","journal-title":"Curr. Opin. Rheumatol."},{"issue":"7","key":"10.1016\/j.jdermsci.2020.12.007_bib0175","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.jdermsci.2020.12.007_bib0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14737159.2019.1571911","article-title":"Soluble CD163 is a potential biomarker in systemic sclerosis","volume":"19","author":"Matsushita","year":"2019","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.jdermsci.2020.12.007_bib0185","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0030-1255354","article-title":"Macrophages: master regulators of inflammation and fibrosis","volume":"30","author":"Wynn","year":"2010","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jdermsci.2020.12.007_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.jdermsci.2020.12.007_bib0195","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function","volume":"25","author":"De Vries","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.jdermsci.2020.12.007_bib0200","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11926-011-0215-5","article-title":"Dendritic cells: novel players in fibrosis and scleroderma","volume":"14","author":"Lu","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"issue":"9","key":"10.1016\/j.jdermsci.2020.12.007_bib0205","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98380","article-title":"pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis","volume":"3","author":"Kafaja","year":"2018","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.jdermsci.2020.12.007_bib0210","doi-asserted-by":"crossref","first-page":"13008","DOI":"10.1074\/jbc.M210366200","article-title":"Connective tissue growth factor gene regulation: requirements for its induction by transforming growth factor-\u03b22 in fibroblasts","volume":"278","author":"Leask","year":"2003","journal-title":"J. Biol. Chem."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181120304266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181120304266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:50:47Z","timestamp":1760331047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181120304266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0923181120304266"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.12.007","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}